Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3375837 | 0.98 | SIGMAR1 (0.43) | SIGMAR1HSD11B1EPHX2EPHX1TSHR | |
| SCHEMBL2638366 | 0.97 | EPHX2 (0.43) | SIGMAR1HSD11B1EPHX2EPHX1TSHR | |
| SCHEMBL3378312 | 0.84 | HSD11B1 (0.40) | SIGMAR1HSD11B1EPHX2EPHX1TSHR | |
| SCHEMBL3375706 | 0.83 | PBK (0.41) | SIGMAR1HSD11B1EPHX2EPHX1TSHR | |
| SCHEMBL3375841 | 0.82 | EPHX1 (0.42) | SIGMAR1HSD11B1EPHX2EPHX1TSHR | |
| SCHEMBL15105751 | 0.81 | HSD11B1 (0.39) | SIGMAR1HSD11B1EPHX2EPHX1TSHR | |
| SCHEMBL3378749 | 0.81 | HSD11B1 (0.40) | SIGMAR1HSD11B1EPHX2EPHX1TSHR | |
| SCHEMBL2638324 | 0.81 | HSD11B1 (0.40) | SIGMAR1HSD11B1EPHX2EPHX1TSHR | |
| SCHEMBL2638872 | 0.80 | EPHX2 (0.57) | SIGMAR1HSD11B1EPHX2EPHX1TSHR | |
| SCHEMBL2638369 | 0.80 | EPHX2 (0.41) | SIGMAR1HSD11B1EPHX2EPHX1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2310356-B1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | LUNDBECK & CO AS H (DK) | 2013-08-14 | — | — | EP | claimed |
| US-20100022546-A1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2010-01-28 | — | — | US | claimed |
| US-8716284-B2 | Adamantyl diamide derivatives and uses of same | H. LUNDBECK A/S (DK) | 2014-05-06 | — | — | US | disclosed |
| US-20130184277-A1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2013-07-18 | — | — | US | disclosed |
| US-8198275-B2 | Adamantyl diamide derivatives and uses of same | H. LUNDBECK A/S (DK) | 2012-06-12 | — | — | US | disclosed |
| US-20100022546-A1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184277-A1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | QDPR, PDE3B, ADM2 | SIGMAR1 1322/4885HSD11B1 386/4885EPHX2 1871/4885 |
| US-20100022546-A1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | QDPR, ADM2, PDE3B | SIGMAR1 1487/4885HSD11B1 318/4885EPHX2 1923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.